Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF, Blok EJ, Charehbili A, Engels CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers GJ, Nortier JWR, Kuppen PJK, van der Burg SH, Kroep JR. de Groot AF, et al. Among authors: smit vthbm. Breast Cancer Res Treat. 2019 Jun;175(3):605-615. doi: 10.1007/s10549-019-05195-y. Epub 2019 Mar 13. Breast Cancer Res Treat. 2019. PMID: 30868392 Free PMC article.
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A, Wasser MN, Smit VT, Putter H, van Leeuwen-Stok AE, Meershoek-Klein Kranenbarg WM, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR. Charehbili A, et al. Eur J Surg Oncol. 2014 Oct;40(10):1216-21. doi: 10.1016/j.ejso.2014.07.036. Epub 2014 Aug 8. Eur J Surg Oncol. 2014. PMID: 25150151 Clinical Trial.
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR. de Groot S, et al. Breast Cancer Res Treat. 2015 Jan;149(2):461-6. doi: 10.1007/s10549-014-3256-4. Epub 2015 Jan 4. Breast Cancer Res Treat. 2015. PMID: 25556355 Free PMC article. Clinical Trial.
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC, Charehbili A, van de Velde CJ, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ. Engels CC, et al. Breast Cancer Res Treat. 2015 Feb;149(3):587-96. doi: 10.1007/s10549-015-3269-7. Epub 2015 Jan 24. Breast Cancer Res Treat. 2015. PMID: 25616355 Free PMC article. Clinical Trial.
Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
Dekker TJ, Charehbili A, Smit VT, ten Dijke P, Kranenbarg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR. Dekker TJ, et al. Mol Oncol. 2015 Jun;9(6):1120-8. doi: 10.1016/j.molonc.2015.02.001. Epub 2015 Feb 14. Mol Oncol. 2015. PMID: 25735561 Free PMC article. Clinical Trial.
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Charehbili A, et al. Breast. 2016 Feb;25:69-74. doi: 10.1016/j.breast.2015.10.005. Epub 2015 Nov 21. Breast. 2016. PMID: 26614548 Clinical Trial.
165 results